These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
881 related articles for article (PubMed ID: 28718981)
21. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma. Brüggenjürgen B; Reinhold T; Brehler R; Laake E; Wiese G; Machate U; Willich SN Ann Allergy Asthma Immunol; 2008 Sep; 101(3):316-24. PubMed ID: 18814456 [TBL] [Abstract][Full Text] [Related]
22. Preventive capacity of allergen immunotherapy on the natural history of allergy. Incorvaia C J Prev Med Hyg; 2013 Jun; 54(2):71-4. PubMed ID: 24396984 [TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of house dust mite allergen immunotherapy in children with allergic asthma. Farraia M; Paciência I; Castro Mendes F; Cavaleiro Rufo J; H Shamji M; Agache I; Moreira A Allergy; 2022 Sep; 77(9):2688-2698. PubMed ID: 35451128 [TBL] [Abstract][Full Text] [Related]
24. The local and systemic side-effects of venom and inhaled-allergen subcutaneous immunotherapy. Adamic K; Zidarn M; Bajrovic N; Erzen R; Kopac P; Music E Wien Klin Wochenschr; 2009; 121(9-10):357-60. PubMed ID: 19562302 [TBL] [Abstract][Full Text] [Related]
25. Real-world benefits of allergen immunotherapy for birch pollen-associated allergic rhinitis and asthma. Wahn U; Bachert C; Heinrich J; Richter H; Zielen S Allergy; 2019 Mar; 74(3):594-604. PubMed ID: 30183091 [TBL] [Abstract][Full Text] [Related]
26. Approach to Patients with Allergic Rhinitis: Testing and Treatment. Cox L Med Clin North Am; 2020 Jan; 104(1):77-94. PubMed ID: 31757239 [TBL] [Abstract][Full Text] [Related]
27. Safety of specific immunotherapy using an ultra-rush induction regimen in bee and wasp allergy. Bożek A; Kołodziejczyk K Hum Vaccin Immunother; 2018 Feb; 14(2):288-291. PubMed ID: 29106324 [TBL] [Abstract][Full Text] [Related]
28. Allergen-specific immunotherapy of Hymenoptera venom allergy - also a matter of diagnosis. Schiener M; Graessel A; Ollert M; Schmidt-Weber CB; Blank S Hum Vaccin Immunother; 2017 Oct; 13(10):2467-2481. PubMed ID: 28604163 [TBL] [Abstract][Full Text] [Related]
30. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews. Nurmatov U; Dhami S; Arasi S; Roberts G; Pfaar O; Muraro A; Ansotegui IJ; Calderon M; Cingi C; Durham S; van Wijk RG; Halken S; Hamelmann E; Hellings P; Jacobsen L; Knol E; Larenas-Linnemann D; Lin SY; Maggina V; Oude-Elberink H; Pajno G; Panwankar R; Pastorello E; Pitsios C; Rotiroti G; Timmermans F; Tsilochristou O; Varga EM; Wilkinson J; Williams A; Worm M; Zhang L; Sheikh A Clin Transl Allergy; 2017; 7():24. PubMed ID: 28794855 [TBL] [Abstract][Full Text] [Related]
31. Immunotherapy in allergic rhinitis and lower airway outcomes. Cardona V; Luengo O; Labrador-Horrillo M Allergy; 2017 Jan; 72(1):35-42. PubMed ID: 27439141 [TBL] [Abstract][Full Text] [Related]
32. A Cost-Minimisation Analysis Comparing Sublingual Immunotherapy to Subcutaneous Immunotherapy for the Treatment of House Dust Mite Allergy in a Swedish Setting. Björstad Å; Cardell LO; Hahn-Pedersen J; Svärd M Clin Drug Investig; 2017 Jun; 37(6):541-549. PubMed ID: 28326466 [TBL] [Abstract][Full Text] [Related]
34. House Dust Mite Sublingual Immunotherapy for Pediatric Patients With Allergic Asthma. Richards JR; Stumpf JL Ann Pharmacother; 2018 Oct; 52(10):1019-1030. PubMed ID: 29642713 [TBL] [Abstract][Full Text] [Related]
35. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective. Goldberg A; Yogev A; Confino-Cohen R Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964 [TBL] [Abstract][Full Text] [Related]
36. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma. Agache I; Lau S; Akdis CA; Smolinska S; Bonini M; Cavkaytar O; Flood B; Gajdanowicz P; Izuhara K; Kalayci O; Mosges R; Palomares O; Papadopoulos NG; Sokolowska M; Angier E; Fernandez-Rivas M; Pajno G; Pfaar O; Roberts GC; Ryan D; Sturm GJ; van Ree R; Varga EM; van Wijk RG; Yepes-Nuñez JJ; Jutel M Allergy; 2019 May; 74(5):855-873. PubMed ID: 31095767 [TBL] [Abstract][Full Text] [Related]
37. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper. Shamji MH; Kappen JH; Akdis M; Jensen-Jarolim E; Knol EF; Kleine-Tebbe J; Bohle B; Chaker AM; Till SJ; Valenta R; Poulsen LK; Calderon MA; Demoly P; Pfaar O; Jacobsen L; Durham SR; Schmidt-Weber CB Allergy; 2017 Aug; 72(8):1156-1173. PubMed ID: 28152201 [TBL] [Abstract][Full Text] [Related]
38. EAACI guidelines on allergen immunotherapy: Prevention of allergy. Halken S; Larenas-Linnemann D; Roberts G; Calderón MA; Angier E; Pfaar O; Ryan D; Agache I; Ansotegui IJ; Arasi S; Du Toit G; Fernandez-Rivas M; Geerth van Wijk R; Jutel M; Kleine-Tebbe J; Lau S; Matricardi PM; Pajno GB; Papadopoulos NG; Penagos M; Santos AF; Sturm GJ; Timmermans F; van Ree R; Varga EM; Wahn U; Kristiansen M; Dhami S; Sheikh A; Muraro A Pediatr Allergy Immunol; 2017 Dec; 28(8):728-745. PubMed ID: 28902467 [TBL] [Abstract][Full Text] [Related]
39. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. Calderon MA; Casale TB; Nelson HS; Demoly P J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829 [TBL] [Abstract][Full Text] [Related]
40. Allergen immunotherapy: an update on protocols of administration. Larenas-Linnemann D Curr Opin Allergy Clin Immunol; 2015 Dec; 15(6):556-67. PubMed ID: 26485100 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]